Category - Developments

Developments

RenovoRx advances TAMP into borderline resectable PDAC

RenovoRX (NASDAQ: RNXT) has announced that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont (UVM) evaluating the approved chemotherapy gemcitabine...

October 7, 2026

Developments

PacBio and TychoBio collaborate to train AI models for rare disease therapeutics

PacBio (NASDAQ: PACB) and closely held TychoBio have announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio...

October 6, 2026

Developments

Saluda announces U.S. availability of first and only closed-loop surgical paddle

Saluda Medical (ASX: SLD) has announced the full U.S. commercial release of the FDA-approved CAP24 Surgical Paddle Lead making it available to neurosurgery and orthopedic spine practices in selected centers...

October 6, 2026

Developments

Wandercraft acquires Esko Bionics advancing robotic mobility

Closely held Wandercraft has announced the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation (NASDAQ: CHRN), uniting two leaders in robotic mobility to form the world’s leading medical...

October 2, 2026

Developments

FDA clears IND application for Surrozen’s SZN-8141 in DME

Surrozen (NASDAQ: SRZN) has announced its Investigational New Drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME) has become effective, enabling advancement to clinical development. SZN...

October 2, 2026

Developments

Tenon launches titanium 3D-printed lateral screw

Tenon Medical (NASDAQ: TNON) has announced the full commercial launch of its new titanium 3D-printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the...

September 30, 2026

Developments

Connect reports positive data from study of rademikibart in COPD

Connect Biopharma (NASDAQ: CNTB) has announced topline results from its global Phase 2 study evaluating rademikibart, its next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody as...

September 30, 2026

Developments

Valion sees potential for multi-fold expansion of long-term opportunity after successful joint formulation of oral mucosal Entolimod for acute radiation syndrome

Valion Bio (NASDAQ: VBIO) and closely held Shear Kershman Laboratories (SKL) announced the successful completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of...

September 30, 2026

Developments

Immix reports 89% CR in trial of NXC-201 in R/R AL amyloidosis

Immix Biopharma (NASDAQ: IMMX) has reported interim data showing an 89% complete response (CR) rate across all 45 enrolled patients, based on an assessment by an independent review committee, from its NEXICART-2 Phase 2...

September 29, 2026

Developments

Codexis enters agreement with drug innovator to create stereo-defined siRNA

Codexis (NASDAQ: CDXS) has announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. According to Codexis, the agreement...

September 28, 2026

Category - Developments

Subscribe